Education-only orientation — This page is part of the iMicrodosing.org evidence library. It provides research and regulatory education only. It is not clinical advice, prescribing information, a recommendation to seek or avoid any treatment, or guidance on participating in any clinical program.
What this page does and does not contain — This page examines the clinical and regulatory landscape for psilocybin-based investigational drugs. It names clinical sponsors and trial programs only to identify their public research records and regulatory milestones. It does not: recommend or endorse any treatment, drug, or program; guide readers toward or away from any investigational therapy; facilitate trial enrollment; provide recruitment or site-location information; reproduce or endorse sponsor investor language as established efficacy; apply full-dose clinical trial findings to microdosing; or link to
.comcommerce properties.
Phase 2 trials explore safety and preliminary efficacy in smaller samples. Phase 3 trials test efficacy in larger, randomized, controlled designs to support a regulatory application. The distinction determines the evidentiary weight placed on a result. A Phase 2 psilocybin finding cannot substitute for a Phase 3 finding in the approval pathway, and Phase 3 results in one indication do not establish efficacy in others. [1] primary-regulatory Psychedelic Drugs: Considerations for Clinical Investigations Link →
Why clinical phases exist
The FDA’s drug development pathway structures research into phases that build on each other to answer progressively harder questions. Phase 1 addresses safety and dosing in small groups. Phase 2 explores whether a drug shows a biological effect in the target condition and identifies a dosing range worth testing at scale. Phase 3 runs large randomized controlled trials to establish efficacy and safety at the level needed to support a formal marketing application. [1] primary-regulatory Psychedelic Drugs: Considerations for Clinical Investigations Link →
Each phase is not just a larger version of the previous one — it asks a different question. Phase 2 asks “does this look promising enough to justify a Phase 3?” Phase 3 asks “does this actually work under controlled conditions that could support regulatory approval?” These are different standards.
| Feature | Phase 2 | Phase 3 |
|---|---|---|
| Typical sample size | Tens to hundreds of participants | Hundreds to over a thousand |
| Primary purpose | Preliminary efficacy; dose selection | Efficacy and safety confirmation |
| Design | May be open-label or smaller RCT | Randomized, double-blind, placebo- or comparator-controlled |
| Regulatory weight | Supportive; not sufficient alone for approval | Pivotal; sufficient for NDA if pre-specified endpoints met |
| Example in psilocybin | COMP001 Phase 2b (Goodwin et al., NEJM 2022) | COMP005 and COMP006 (Compass Pathways, 2025–2026) |
What a pre-specified endpoint is and why it matters
A pre-specified primary endpoint is the outcome measure designated before a trial begins as the single measure the trial is powered and designed to detect. Pre-specification prevents data-dredging — the practice of testing many outcomes and reporting the best-looking one. Regulatory agencies treat results on pre-specified primary endpoints at Phase 3 differently from exploratory or secondary outcomes precisely because pre-specification is a safeguard against selective reporting.
In the COMP005 Phase 3 trial, the pre-specified primary endpoint was the difference in change from baseline on the Montgomery-Åsberg Depression Rating Scale between the COMP360 25 mg arm and the placebo arm at six weeks. [2] sponsor-press-release Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression Link → Meeting a pre-specified primary endpoint in a randomized, double-blind, placebo-controlled Phase 3 trial is the most robust category of evidence in drug development — and it is still bounded by the conditions of that trial.
Understanding MADRS and effect sizes
The Montgomery-Åsberg Depression Rating Scale is a 0-to-60 clinician-rated instrument that measures the severity of depressive symptoms across ten domains. Higher scores indicate greater severity. A mean treatment difference of minus 3.6 points at week 6 for COMP360 25 mg versus placebo in COMP005 is a statistically significant result (p less than 0.001). [2] sponsor-press-release Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression Link → Interpreting the clinical meaningfulness of that difference requires understanding what 3.6 points on a 60-point scale represents in the context of how the scale is used and how other approved treatments compare — that evaluation is ongoing in the clinical and regulatory literature.
Blinding challenges in psychedelic trials
Psychedelic trials face a specific methodological challenge: participants who receive an active dose of a psychedelic substance generally know it, because the subjective experience is obvious. This “functional unblinding” complicates the standard double-blind design. Researchers have used active comparators — such as a very low dose of the same compound — to reduce this effect, but the degree of blinding achieved and its impact on results is an area of active scientific discussion. [1] primary-regulatory Psychedelic Drugs: Considerations for Clinical Investigations Link →
The FDA’s 2023 guidance on psychedelic drug clinical investigations addresses these challenges explicitly. That the FDA published specific methodological guidance reflects the seriousness with which these design questions are being engaged, not the absence of standards.
Why phase matters for reading psilocybin news
Many media reports omit or obscure which phase a study belongs to, presenting Phase 2 open-label findings with the same language used for pivotal Phase 3 results. The Phase 2b COMP001 study established promising evidence for psilocybin in treatment-resistant depression [3] Clinical trial Single-dose psilocybin for a treatment-resistant episode of major depression doi:10.1056/NEJMoa2206443 — but that result alone was not sufficient for a regulatory application. Phase 3 was required. Similarly, the Phase 2 psilocybin-versus-escitalopram study by Carhart-Harris and colleagues [4] Clinical trial Trial of psilocybin versus escitalopram for depression doi:10.1056/NEJMoa2032994 is a head-to-head comparison study, a different design from a placebo-controlled Phase 3 with a pre-specified regulatory endpoint. Each study contributes differently to the evidence base and should be cited for what it established under its own conditions.
See the How to Read Press Releases page for a practical framework. See the Clinical Pipeline overview for where each program currently stands.
- Phase 2b
- A subdivision of Phase 2 that typically involves larger samples and more formal efficacy testing than Phase 2a, often used to determine Phase 3 dose and design. Results are still preliminary relative to Phase 3.
- Active comparator
- A control condition using a low dose of the same drug rather than an inert substance. Used in psychedelic trials to address functional unblinding, but its use affects how effect sizes are interpreted.
- Statistical significance vs. clinical significance
- Statistical significance (p-value below a threshold) means the result is unlikely to be due to chance at the tested sample size. Clinical significance is a judgment about whether the magnitude of the effect matters meaningfully in practice. A result can be statistically significant without being clinically meaningful, and vice versa.
- Generalizability
- Whether the results of a trial apply beyond the specific population, dose, and conditions studied. Phase 3 results in treatment-resistant depression do not generalize to major depressive disorder, PTSD, or other conditions without separate evidence.